EBS Emergent Biosolutions Inc.

54.23
+1.76  (+3%)
Previous Close 52.47
Open 52.62
Price To Book 2.83
Market Cap 2,798,268,000
Shares 51,600,000
Volume 275,738
Short Ratio 3.95
Av. Daily Volume 465,981
Stock charts supplied by TradingView

NewsSee all news

  1. Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate

    GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company's chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was

  2. Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019

    GAITHERSBURG, Md., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the

  3. Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder

    GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National

  4. Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference

    GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that members of the company's senior management team will participate in the Cantor Fitzgerald Global

  5. Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense

    GAITHERSBURG, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to commence in 2020.
FLU-IGIV
Influenza A
Approved May 17, 2012.
BioThrax
Anthrax Vaccine
Approved November 24, 2015.
BioThrax
Anthrax Vaccine Adsorbed
Approved March 25, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Anthrax
Phase 1 data released November 19, 2018 - primary endpoint met with favorable safety profile.
VLA1601
Zika vaccine
Phase 3 trial planned for 2019.
NuThrax
Anthrax vaccine
Phase 2 interim analysis April 16, 2019.
CHIKV-VLP
Chikungunya virus

Latest News

  1. Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate

    GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company's chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was

  2. Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019

    GAITHERSBURG, Md., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the

  3. Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder

    GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National

  4. Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference

    GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that members of the company's senior management team will participate in the Cantor Fitzgerald Global

  5. Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense

    GAITHERSBURG, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing

  6. Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile

    Reaffirms ACAM2000 as a key component of the U.S. preparedness stance against the threat of smallpox as a biologic weaponSupports the government's continued efforts and long-term strategy to maintain sufficient